MRI of carotid atherosclerosis: Clinical implications and future directions

Nature Reviews Cardiology

Volumn 7, Issue 3, 2010, Pages 165-173

  Underhill, Hunter R ^a   Hatsukami, Thomas S ^a   Fayad, Zahi A ^b   Fuster, Valentin ^c   Yuan, Chun ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESEVELAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICOTINIC ACID; PLACEBO; ROSUVASTATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD FLOW; BRAIN INFARCTION; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RELIABILITY; REMISSION; REVIEW; VALIDATION PROCESS;

CAROTID ARTERIES; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77649183826     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.246     Document Type: Review

References (114)

1. American Heart Association. Heart Disease & Stroke Statistics-2009 Update (American Heart Association, Dallas, TX, 2009).
2. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N. Engl. J. Med. 325, 445-453 (1991).
3. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 337, 1235-1243 (1991).
4. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273, 1421-1428 (1995).
5. Rothwell, P. M., Gutnikov, S. A. & Warlow, C. P. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 34, 514-523 (2003).
6. Gorelick, P. B. Carotid endarterectomy: where do we draw the line? Stroke 30, 1745-1750 (1999).
7. Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R. & Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371-1375 (1987). (Pubitemid 17079680)
8. Pignoli, P., Tremoli, E., Poli, A., Oreste, P. & Paoletti, R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74, 1399-1406 (1986).
9. O'Leary, D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
10. Landry, A., Spence, J. D. & Fenster, A. Measurement of carotid plaque volume by 3-dimensional ultrasound. Stroke 35, 864-869 (2004).
11. Saba, L., Sanfilippo, R., Montisci, R. & Mallarini, G. Carotid artery wall thickness: comparison between sonography and multidetector row CT angiography. Neuroradiology doi:10.1007/s00234-009-0589-5.
12. Toussaint, J. F., Southern, J. F., Fuster, v. & Kantor, H. L. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15, 1533-1542 (1995).
13. Toussaint, J. F., LaMuraglia, G. M., Southern, J. F., Fuster, v. & Kantor, H. L. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 94, 932-938 (1996).
14. Saam, T. et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol. 25, 234-239 (2005).
15. Cai, J. et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrastenhanced magnetic resonance imaging and histology. Circulation 112, 3437-3444 (2005).
16. Yuan, C. et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipidrich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 104, 2051-2056 (2001).
17. Trivedi, R. A. et al. Multi-sequence in vivo MRI can quantify fibrous cap and lipid core components in human carotid atherosclerotic plaques. Eur. J. Vasc. Endovasc. Surg. 28, 207-213 (2004).
18. Chu, B. et al. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 35, 1079-1084 (2004).
19. Kampschulte, A. et al. Differentiation of intraplaque versus juxtaluminal hemorrhage/ thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation 110, 3239-3244 (2004).
20. Moody, A. R. et al. Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation 107, 3047-3052 (2003).
21. Ota, H. et al. Carotid intraplaque hemorrhage imaging at 3.0-tesla MRI: a comparison of three T1-weighted sequences. Radiology (in press).
22. Hatsukami, T. S., Ross, R., Polissar, N. L. & Yuan, C. visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 102, 959-964 (2000).
23. Mitsumori, L. M. et al. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. J. Magn. Reson. Imaging 17, 410-420 (2003).
24. Yu, W. et al. The added value of longitudinal black-blood cardiovascular magnetic resonance angiography in the cross sectional identification of carotid atherosclerotic ulceration. J. Cardiovasc. Magn. Reson. 11, 31 (2009).
25. Saam, T. et al. Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5T Siemens, Philips, and General Electric scanners. J. Magn. Reson. Imaging 26, 344-352 (2007).
26. Takaya, N. et al. Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J. Magn. Reson. Imaging 24, 203-210 (2006).
27. Saam, T. et al. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J. Cardiovasc. Magn. Reson. 7, 799-808 (2005).
28. Underhill, H. R. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155, 584.e1-8 (2008).
29. Underhill, H. R. et al. Carotid plaque morphology and composition: initial comparison between 1.5- and 3.0-T magnetic field strengths. Radiology 248, 550-560 (2008).
30. Kang, X., Polissar, N. L., Han, C., Lin, E. & Yuan, C. Analysis of the measurement precision of arterial lumen and wall areas using high-resolution MRI. Magn. Reson. Med. 44, 968-972 (2000).
31. Chu, B. et al. Cardiac magnetic resonance features of the disruption-prone and the disrupted carotid plaque. J. Am. Coll. Cardiol. Imag. 2, 883-896 (2009).
32. Yuan, C. et al. MRI of atherosclerosis in clinical trials. NMR Biomed. 19, 636-654 (2006).
33. Saam, T. et al. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology 244, 64-77 (2007). (Pubitemid 46981959)
34. Fayad, Z. A. & Fuster, v. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ. Res. 89, 305-316 (2001). (Pubitemid 34132668)
35. Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
36. Takaya, N. et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111, 2768-2775 (2005).
37. Underhill, H. R. et al. Predictors of surface disruption with MR imaging in asymptomatic carotid artery stenosis. AJNR Am. J. Neuroradiol. doi:10.3174/ajnr.A1842.
38. Underhill, H. R. et al. Arterial remodeling in subclinical carotid artery disease. J. Am. Coll. Cardiol. Imag 2, 1381-1389 (2009).
39. Takaya, N. et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI--initial results. Stroke 37, 818-823 (2006).
40. Singh, N. et al. Moderate carotid artery stenosis: MR imaging-depicted intraplaque hemorrhage predicts risk of cerebrovascular ischemic events in asymptomatic men. Radiology 252, 502-508 (2009).
41. Altaf, N. et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. J. Vasc. Surg. 47, 337-342 (2008).
42. Imparato, A. M., Riles, T. S. & Gorstein, F. The carotid bifurcation plaque: pathologic findings associated with cerebral ischemia. Stroke 10, 238-245 (1979).
43. Lusby, R. J., Ferrell, L. D., Ehrenfeld, W. K., Stoney, R. J. & Wylie, E. J. Carotid plaque hemorrhage. Its role in production of cerebral ischemia. Arch. Surg. 117, 1479-1488 (1982).
44. Imparato, A. M., Riles, T. S., Mintzer, R. & Baumann, F. G. The importance of hemorrhage in the relationship between gross morphologic characteristics and cerebral symptoms in 376 carotid artery plaques. Ann. Surg. 197, 195-203 (1983).
45. Lennihan, L. et al. Lack of association between carotid plaque hematoma and ischemic cerebral symptoms. Stroke 18, 879-881 (1987).
46. Gao, P., Chen, Z. Q., Bao, Y. H., Jiao, L. Q. & Ling, F. Correlation between carotid intraplaque hemorrhage and clinical symptoms: systematic review of observational studies. Stroke 38, 2382-2390 (2007).
47. Golledge, J., Greenhalgh, R. M. & Davies, A. H. The symptomatic carotid plaque. Stroke 31, 774-781 (2000).
48. Moore, W. S. et al. Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. Circulation 91, 566-579 (1995).
49. Zhu, D. C., Ferguson, M. S. & DeMarco, J. K. An optimized 3D inversion recovery prepared fast spoiled gradient recalled sequence for carotid plaque hemorrhage imaging at 3.0 T. Magn. Reson. Imaging 26, 1360-1366 (2008).
50. Bornstein, N. M., Krajewski, A., Lewis, A. J. & Norris, J. W. Clinical significance of carotid plaque hemorrhage. Arch. Neurol. 47, 958-959 (1990).
51. von Maravic, C., Kessler, C., von Maravic, M., Hohlbach, G. & Kompf, D. Clinical relevance of intraplaque hemorrhage in the internal carotid artery. Eur. J. Surg. 157, 185-188 (1991).
52. Saam, T. et al. Prevalence of American Heart Association type vI carotid atherosclerotic lesions identified by magnetic resonance imaging for different levels of stenosis as measured by duplex ultrasound. J. Am. Coll. Cardiol. 51, 1014-1021 (2008).
53. Dong, L. et al. Geometric and compositional appearance of atheroma in an angiographically normal carotid artery in patients with atherosclerosis. AJNR Am. J. Neuroradiol. doi:10.3174/ajnr.A1793.
54. Corti, R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
55. Zhao, X. Q. et al. Magnetic resonance imaging of the plaque lipid depletion during lipid therapy: a prospective assessment of efficacy and time-course. A late breaking clinical trial report presented at ACC 58th Annual Scientific Session, 28-31 March 2009, Orlando, USA.
56. AbuRahma, A. F., Boland, J. P., Robinson, P. & Decanio, R. Antiplatelet therapy and carotid plaque hemorrhage and its clinical implications. J. Cardiovasc. Surg. 31, 66-70 (1990).
57. Arapoglou, B., Kondi-Pafiti, A., Katsenis, K. & Dimakakos, P. The clinical significance of carotid plaque haemorrhage. Int. Angiol. 13, 323-326 (1994).
58. Ammar, A. D. et al. Intraplaque hemorrhage: its significance in cerebrovascular disease. Am. J. Surg. 148, 840-843 (1984).
59. virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275 (2000).
60. Wasserman, B. A., Casal, S. G., Astor, B. C., Aletras, A. H. & Arai, A. E. Wash-in kinetics for gadolinium-enhanced magnetic resonance imaging of carotid atheroma. J. Magn. Reson. Imaging 21, 91-95 (2005).
61. Libby, P. & Theroux, P. Pathophysiology of coronary artery disease. Circulation 111, 3481-3488 (2005).
62. Sitzer, M. et al. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis. Stroke 26, 1231-1233 (1995).
63. Park, A. E., McCarthy, W. J., Pearce, W. H., Matsumura, J. S. & Yao, J. S. Carotid plaque morphology correlates with presenting symptomatology. J. Vasc. Surg. 27, 872-878; discussion 878-879 (1998).
64. Fisher, M. et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke 36, 253-257 (2005).
65. Yuan, C. et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105, 181-185 (2002).
66. Saam, T. et al. Comparison of symptomatic and asymptomatic atherosclerotic carotid plaque features with in vivo MR imaging. Radiology 240, 464-472 (2006).
67. virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18 (2006).
68. Redgrave, J. N., Gallagher, P., Lovett, J. K. & Rothwell, P. M. Critical cap thickness and rupture in symptomatic carotid plaques: the Oxford plaque study. Stroke 39, 1722-1729 (2008).
69. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998).
70. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
71. Amarenco, P. et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006).
72. Corti, R. et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 46, 106-112 (2005).
73. Grobner, T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial. Transplant. 21, 1104-1108 (2006).
74. Rydahl, C., Thomsen, H. S. & Marckmann, P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest. Radiol. 43, 141-144 (2008).
75. Wiginton, C. D. et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am. J. Roentgenol. 190, 1060-1068 (2008).
76. varani, J. et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest. Radiol. 44, 74-81 (2009).
77. Sadowski, E. A. et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243, 148-157 (2007).
78. Paterson, J. C. Capillary rupture with intimal hemorrhage as a causative factor in coronary thrombosis. Arch. Path. 25, 474-487 (1938).
79. Levy, A. P. & Moreno, P. R. Intraplaque hemorrhage. Curr. Mol. Med. 6, 479-488 (2006).
80. Cybulsky, M. I. & Gimbrone, M. A., Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788-791 (1991).
81. Smith, J. D. et al. Decreased atherosclerosis in mice deficient in both macrophage colonystimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92, 8264-8268 (1995).
82. Rajavashisth, T. et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 101, 2702-2710 (1998).
83. Falk, E. Why do plaques rupture? Circulation 86, III30-III42 (1992).
84. Falk, E., Shah, P. K. & Fuster, v. Coronary plaque disruption. Circulation 92, 657-671 (1995).
85. virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the unstable plaque. Prog. Cardiovasc. Dis. 44, 349-356 (2002).
86. Trivedi, R. A. et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxideenhanced MRI. Stroke 35, 1631-1635 (2004).
87. Trivedi, R. A. et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 1601-1606 (2006).
88. Kooi, M. E. et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453-2458 (2003).
89. Tang, T. Y. et al. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke 39, 2144-2147 (2008).
90. Howarth, S. P. et al. Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. Eur. J. Radiol. 70, 555-560 (2009).
91. Tang, T. Y. et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 53, 2039-2050 (2009).
92. Briley-Saebo, K. C. et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117, 3206-3215 (2008).
93. Amirbekian, v. et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104, 961-966 (2007).
94. Chen, W. et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3, 233-242 (2008).
95. Cormode, D. P. et al. An ApoA-I mimetic peptide high-density-lipoprotein- based MRI contrast agent for atherosclerotic plaque composition detection. Small 4, 1437-1444 (2008).
96. Cormode, D. P. et al. Nanocrystal core highdensity lipoproteins: a multimodality contrast agent platform. Nano Lett. 8, 3715-3723 (2008).
97. Padhani, A. R. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J. Magn. Reson. Imaging 16, 407-422 (2002).
98. Kerwin, W. S. et al. Inflammation in carotid atherosclerotic plaque: a dynamic contrastenhanced MR imaging study. Radiology 241, 459-468 (2006).
99. Calcagno, C. et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler. Thromb. Vasc. Biol. 28, 1311-1317 (2008).
100. Zhao, X. Q. et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am. Heart J. 154, 239-246 (2007).
101. Kerwin, W. S., Oikawa, M., Yuan, C., Jarvik, G. P. & Hatsukami, T. S. MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn. Reson. Med. 59, 507-514 (2008).
102. Kumamoto, M., Nakashima, Y. Sueishi, K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum. Pathol. 26, 450-456 (1995).
103. Steinman, D. A. et al. Reconstruction of carotid bifurcation hemodynamics and wall thickness using computational fluid dynamics and MRI. Magn. Reson. Med. 47, 149-159 (2002).
104. Li, Z. Y. et al. Structural analysis and magnetic resonance imaging predict plaque vulnerability: a study comparing symptomatic and asymptomatic individuals. J. Vasc. Surg. 45, 768-775 (2007).
105. Tang, D. et al. 3D MRI-based multicomponent FSI models for atherosclerotic plaques. Ann. Biomed. Eng. 32, 947-960 (2004).
106. Tang, D. et al. Sites of rupture in human atherosclerotic carotid plaques are associated with high structural stresses. An in vivo MRIbased 3D fluid-structure interaction study. Stroke 40, 3258-3263 (2009).
107. Prosi, M., Perktold, K., Ding, Z. & Friedman, M. H. Influence of curvature dynamics on pulsatile coronary artery flow in a realistic bifurcation model. J. Biomech. 37, 1767-1775 (2004).
108. vermeer, S., Koudstaal, P., Oudkerk, M., Hofman, A. & Breteler, M. Prevalence and risk factors of silent brain infarcts in the populationbased Rotterdam Scan Study. Stroke 33, 21-25 (2002). (Pubitemid 34052178)
109. vermeer, S. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34, 1126-1129 (2003).
110. Bernick, C. et al. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology 57, 1222-1229 (2001).
111. Longstreth, W. T. Jr et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 33, 2376-2382 (2002).
112. Brott, T. et al. Baseline silent cerebral infarction in the Asymptomatic Carotid Atherosclerosis Study. Stroke 25, 1122-1129 (1994).
113. Norris, J. & Zhu, C. Silent stroke and carotid stenosis. Stroke 23, 483-485 (1992).
114. Mani, v. et al. Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. J. Cardiovasc. Magn. Reson. 11, 10 (2009).